The development of antiviral therapy and vaccines against respiratory syncytial virus and human parainfluenza virus type 3

Author： A J.E.  

Publisher： Adis International

ISSN： 1364-9027

Source： International Journal of Pharmaceutical Medicine, Vol.15, Iss.4, 2001-08, pp. : 175-190

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of respiratory syncytial virus vaccines

By  

Inpharma, Vol. 1, Iss. 1429, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Respiratory syncytial virus antiviral agents

By Prince G.A.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 6, 1999-06 ,pp. : 753-762

Informa Healthcare

Access to resources Recommend Favorite

An update on respiratory syncytial virus antiviral agents

By Prince G.A.  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 2, 2001-02 ,pp. : 297-308

Informa Healthcare

Access to resources Recommend Favorite

Prophylactic and Therapeutic Approaches Against Respiratory Syncytial Virus

By  

Current Medicinal Chemistry - Anti-Infective Agents, Vol. 4, Iss. 1, 2005-01 ,pp. : 67-73

Bentham Science Publishers

Access to resources Recommend Favorite

Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy

By Bolger Gordon   Lapeyre Nicole   Dansereau Nathalie   Lagacé Lisette   Berry Gerald   Klosowski Katy   Mewhort Tracy   Liuzzi Michel  

Canadian Journal of Physiology and Pharmacology, Vol. 83, Iss. 2, 2005-02 ,pp. : 198-213

NRC Research Press

Access to resources Recommend Favorite